Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis

Int J Cardiol. 2011 Sep 15;151(3):382-3. doi: 10.1016/j.ijcard.2011.06.112. Epub 2011 Jul 18.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Chronic Disease
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Female
  • Humans
  • Inflammation / drug therapy
  • Inflammation / pathology
  • Male
  • Middle Aged
  • Psoriasis / drug therapy*
  • Psoriasis / physiopathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Adalimumab